To address these limitations, we plan to recruit new participants and perform additional measurements to more accurately assess each individual’s condition: (i) expanding biochemical and haematological tests to determine blood cells, organ function biomarkers, and ions; (ii) analysing molecular ageing biomarkers, such as relative telomere length, FOXO3A polymorphisms, and APOE alleles ε2, ε3, and ε4—which also serve as indicators of dementia predisposition; and (iii) evaluating preclinical markers of dementia [44,53]. The gene discussed is APOE; the disease is dementia.